Identiv, Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Identiv, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2017 | Dec 31, 2017 | $60.22M | Mar 29, 2018 |
| FY2017 | Dec 31, 2016 | $56.17M | Mar 29, 2018 |
| FY2016 | Dec 31, 2015 | $60.79M | Mar 28, 2017 |
| FY2015 | Dec 31, 2014 | $81.25M | Mar 31, 2016 |
| FY2013 | Dec 31, 2013 | $19.91M | Mar 31, 2014 |
| FY2013 | Sep 30, 2013 | $21.20M | Mar 31, 2014 |
| FY2013 | Jun 30, 2013 | $18.54M | Mar 31, 2014 |
| FY2013 | Mar 31, 2013 | $15.96M | Mar 31, 2014 |
| FY2013 | Dec 31, 2012 | $21.04M | Mar 31, 2014 |
| FY2013 | Sep 30, 2012 | $17.16M | Mar 31, 2014 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $21.48M | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | $26.63M | Mar 26, 2026 |
| FY2024 | Dec 31, 2023 | $43.45M | Mar 17, 2025 |
| FY2023 | Dec 31, 2022 | $112.92M | Mar 15, 2024 |
| FY2023 | Dec 31, 2021 | $103.77M | Mar 15, 2024 |
| FY2022 | Dec 31, 2020 | $86.92M | Mar 16, 2023 |
| FY2020 | Dec 31, 2019 | $83.76M | Mar 12, 2021 |
| FY2019 | Dec 31, 2018 | $78.14M | Mar 18, 2020 |
| FY2018 | Dec 31, 2017 | $60.22M | Mar 15, 2019 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.31M | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | $340.0K | Mar 26, 2026 |
| FY2024 | Dec 31, 2023 | $6.01M | Mar 17, 2025 |
| FY2023 | Dec 31, 2022 | $40.94M | Mar 15, 2024 |
| FY2023 | Dec 31, 2021 | $37.07M | Mar 15, 2024 |
| FY2022 | Dec 31, 2020 | $33.68M | Mar 16, 2023 |
| FY2020 | Dec 31, 2019 | $36.65M | Mar 12, 2021 |
| FY2019 | Dec 31, 2018 | $33.33M | Mar 18, 2020 |
| FY2018 | Dec 31, 2017 | $22.16M | Mar 15, 2019 |
| FY2017 | Dec 31, 2016 | $23.73M | Mar 29, 2018 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($18.00M) | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | $74.82M | Mar 26, 2026 |
| FY2024 | Dec 31, 2023 | ($5.49M) | Mar 17, 2025 |
| FY2023 | Dec 31, 2022 | ($392.00B) | Apr 29, 2024 |
| FY2023 | Dec 31, 2021 | $1,620.00B | Apr 29, 2024 |
| FY2022 | Dec 31, 2020 | ($5.11M) | Mar 16, 2023 |
| FY2020 | Dec 31, 2019 | ($1.15M) | Mar 12, 2021 |
| FY2019 | Dec 31, 2018 | ($4.71M) | Mar 18, 2020 |
| FY2018 | Dec 31, 2017 | ($8.14M) | Mar 15, 2019 |
| FY2017 | Dec 31, 2016 | ($13.70M) | Mar 29, 2018 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($22.15M) | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | ($27.96M) | Mar 26, 2026 |
| FY2024 | Dec 31, 2023 | ($13.51M) | Mar 17, 2025 |
| FY2023 | Dec 31, 2022 | ($333.0K) | Mar 15, 2024 |
| FY2023 | Dec 31, 2021 | ($1.35M) | Mar 15, 2024 |
| FY2022 | Dec 31, 2020 | ($3.45M) | Mar 16, 2023 |
| FY2020 | Dec 31, 2019 | ($109.0K) | Mar 12, 2021 |
| FY2019 | Dec 31, 2018 | ($1.87M) | Mar 18, 2020 |
| FY2018 | Dec 31, 2017 | ($4.63M) | Mar 15, 2019 |
| FY2017 | Dec 31, 2016 | ($11.22M) | Mar 29, 2018 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $3.28M | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | $3.89M | Mar 26, 2026 |
| FY2024 | Dec 31, 2023 | $4.40M | Mar 17, 2025 |
| FY2023 | Dec 31, 2022 | $9.92M | Mar 15, 2024 |
| FY2023 | Dec 31, 2021 | $8.67M | Mar 15, 2024 |
| FY2022 | Dec 31, 2020 | $9.78M | Mar 16, 2023 |
| FY2020 | Dec 31, 2019 | $8.62M | Mar 12, 2021 |
| FY2019 | Dec 31, 2018 | $7.24M | Mar 18, 2020 |
| FY2018 | Dec 31, 2017 | $6.15M | Mar 15, 2019 |
| FY2017 | Dec 31, 2016 | $6.52M | Mar 29, 2018 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($6.70M) | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | ($15.43M) | Mar 26, 2026 |
| FY2024 | Dec 31, 2023 | $1.16M | Mar 17, 2025 |
| FY2023 | Dec 31, 2022 | ($7.81M) | Mar 15, 2024 |
| FY2023 | Dec 31, 2021 | $1.23M | Mar 15, 2024 |
| FY2022 | Dec 31, 2020 | ($1.77M) | Mar 16, 2023 |
| FY2020 | Dec 31, 2019 | $427.0K | Mar 12, 2021 |
| FY2019 | Dec 31, 2018 | ($5.20M) | Mar 18, 2020 |
| FY2018 | Dec 31, 2017 | ($7.71M) | Mar 15, 2019 |
| FY2017 | Dec 31, 2016 | ($6.22M) | Mar 29, 2018 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $151.34M | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | $163.23M | Mar 26, 2026 |
| FY2024 | Dec 31, 2023 | $109.72M | Mar 17, 2025 |
| FY2023 | Dec 31, 2022 | $102.77M | Mar 15, 2024 |
| FY2022 | Dec 31, 2021 | $96.66M | Mar 16, 2023 |
| FY2021 | Dec 31, 2020 | $78.68M | Mar 14, 2022 |
| FY2020 | Dec 31, 2019 | $74.32M | Mar 12, 2021 |
| FY2019 | Dec 31, 2018 | $66.31M | Mar 18, 2020 |
| FY2018 | Dec 31, 2017 | $51.36M | Mar 15, 2019 |
| FY2017 | Dec 31, 2016 | $40.60M | Mar 29, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $10.64M | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | $9.16M | Mar 26, 2026 |
| FY2024 | Dec 31, 2023 | $35.45M | Mar 17, 2025 |
| FY2023 | Dec 31, 2022 | $27.37M | Mar 15, 2024 |
| FY2022 | Dec 31, 2021 | $22.15M | Mar 16, 2023 |
| FY2021 | Dec 31, 2020 | $44.49M | Mar 14, 2022 |
| FY2020 | Dec 31, 2019 | $38.85M | Mar 12, 2021 |
| FY2019 | Dec 31, 2018 | $32.61M | Mar 18, 2020 |
| FY2018 | Dec 31, 2017 | $27.51M | Mar 15, 2019 |
| FY2017 | Dec 31, 2016 | $36.67M | Mar 29, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $140.70M | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | $154.07M | Mar 26, 2026 |
| FY2025 | Dec 31, 2023 | $74.27M | Mar 26, 2026 |
| FY2024 | Dec 31, 2022 | $75.39M | Mar 17, 2025 |
| FY2023 | Dec 31, 2021 | $74.51M | Mar 15, 2024 |
| FY2023 | Dec 31, 2020 | $34.19M | Mar 15, 2024 |
| FY2022 | Dec 31, 2019 | $35.47M | Mar 16, 2023 |
| FY2019 | Dec 31, 2018 | $33.87M | Mar 18, 2020 |
| FY2018 | Dec 31, 2017 | $24.03M | Mar 15, 2019 |
| FY2017 | Dec 31, 2016 | $4.11M | Mar 29, 2018 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2023 | Dec 31, 2023 | $10.22M | Mar 15, 2024 |
| FY2023 | Dec 31, 2022 | $10.19M | Mar 15, 2024 |
| FY2023 | Dec 31, 2021 | $10.27M | Mar 15, 2024 |
| FY2022 | Dec 31, 2020 | $10.27M | Mar 16, 2023 |
| FY2021 | Dec 31, 2019 | $10.24M | Mar 14, 2022 |
| FY2019 | Dec 31, 2018 | $9.29M | Mar 18, 2020 |
| FY2016 | Dec 31, 2014 | $8.85M | Mar 28, 2017 |
| FY2014 | Dec 31, 2013 | $8.99M | Mar 23, 2015 |
| FY2014 | Dec 31, 2012 | $45.27M | Mar 23, 2015 |
| FY2013 | Dec 31, 2011 | $59.04M | Mar 31, 2014 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($358.05M) | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | ($340.05M) | Mar 26, 2026 |
| FY2024 | Dec 31, 2023 | ($414.87M) | Mar 17, 2025 |
| FY2023 | Dec 31, 2022 | ($409.38M) | Mar 15, 2024 |
| FY2022 | Dec 31, 2021 | ($408.99M) | Mar 16, 2023 |
| FY2021 | Dec 31, 2020 | ($410.61M) | Mar 14, 2022 |
| FY2020 | Dec 31, 2019 | ($405.50M) | Mar 12, 2021 |
| FY2019 | Dec 31, 2018 | ($404.35M) | Mar 18, 2020 |
| FY2018 | Dec 31, 2017 | ($399.65M) | Mar 15, 2019 |
| FY2017 | Dec 31, 2016 | ($391.51M) | Mar 29, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $128.61M | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | $135.65M | Mar 26, 2026 |
| FY2024 | Dec 31, 2023 | $23.31M | Mar 17, 2025 |
| FY2023 | Dec 31, 2022 | $16.65M | Mar 15, 2024 |
| FY2022 | Dec 31, 2021 | $28.55M | Mar 16, 2023 |
| FY2021 | Dec 31, 2020 | $11.41M | Mar 14, 2022 |
| FY2020 | Dec 31, 2019 | $9.38M | Mar 12, 2021 |
| FY2019 | Dec 31, 2018 | $10.87M | Mar 18, 2020 |
| FY2018 | Dec 31, 2017 | $19.05M | Mar 15, 2019 |
| FY2018 | Dec 31, 2016 | $9.12M | Mar 15, 2019 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2014 | Dec 31, 2014 | $13.94M | Mar 23, 2015 |
| FY2014 | Dec 31, 2013 | $6.02M | Mar 23, 2015 |
| FY2012 | Dec 31, 2012 | $14.33M | Mar 19, 2013 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | 3 | Mar 26, 2026 |
| FY2024 | Dec 31, 2023 | 0 | Mar 17, 2025 |
| FY2023 | Dec 31, 2022 | 0 | Mar 15, 2024 |
| FY2023 | Dec 31, 2021 | 0 | Mar 15, 2024 |
| FY2022 | Dec 31, 2020 | 0 | Mar 16, 2023 |
| FY2020 | Dec 31, 2019 | 0 | Mar 12, 2021 |
| FY2019 | Dec 31, 2018 | 0 | Mar 18, 2020 |
| FY2018 | Dec 31, 2017 | 0 | Mar 15, 2019 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | 3 | Mar 26, 2026 |
| FY2024 | Dec 31, 2023 | 0 | Mar 17, 2025 |
| FY2023 | Dec 31, 2022 | 0 | Mar 15, 2024 |
| FY2023 | Dec 31, 2021 | 0 | Mar 15, 2024 |
| FY2022 | Dec 31, 2020 | 0 | Mar 16, 2023 |
| FY2020 | Dec 31, 2019 | 0 | Mar 12, 2021 |
| FY2019 | Dec 31, 2018 | 0 | Mar 18, 2020 |
| FY2018 | Dec 31, 2017 | 0 | Mar 15, 2019 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 23.77M | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | 23.43M | Mar 26, 2026 |
| FY2024 | Dec 31, 2023 | 23.25M | Mar 17, 2025 |
| FY2023 | Dec 31, 2022 | 22.62M | Mar 15, 2024 |
| FY2022 | Dec 31, 2021 | 22.23M | Mar 16, 2023 |
| FY2021 | Dec 31, 2020 | 18.06M | Mar 14, 2022 |
| FY2020 | Dec 31, 2019 | 16.99M | Mar 12, 2021 |
| FY2019 | Dec 31, 2018 | 15.97M | Mar 18, 2020 |
| FY2018 | Dec 31, 2017 | 14.44M | Mar 15, 2019 |
| FY2017 | Dec 31, 2016 | 11.11M | Mar 29, 2018 |